Observed differences could be, at least partially, explained by therapeutic interventions—majority of our RA patients have been treated with DMARDs and/or steroids with such therapies being described as promoting IL-1RA secretion [58]. This evidence concerns the gene IL1R1 and rheumatoid arthritis.